Group-Based Contingency Management for Substance Abuse Treatment - 1
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the efficacy of prize-based contingency management (CM) when administered exclusively in groups. Substance dependent patients (N=360) at community-based treatment programs are randomly assigned to one of two conditions: (a) standard, non-CM treatment or (b) standard treatment plus prize CM delivered in groups. In the CM condition, patients earn the opportunity to win prizes for attending groups and submitting drug-free biological specimens. Substance use and psychosocial problems are measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up evaluations. We also assess patient characteristics that may be associated with improved outcomes within and across conditions.
| Condition | Intervention |
|---|---|
|
Substance Abuse |
Behavioral: Contingency management |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Group-Based Contingency Management for Substance Abuse Treatment |
- Drug use [ Time Frame: baseline and at each follow-up ] [ Designated as safety issue: No ]
- Retention [ Time Frame: each follow-up ] [ Designated as safety issue: No ]
| Enrollment: | 312 |
| Study Start Date: | May 2005 |
| Study Completion Date: | January 2010 |
| Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
-
Behavioral: Contingency management
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion criteria:
- age > 18 years
- current DSM-IV diagnosis of cocaine, opioid or alcohol abuse or dependence
- willing to provide breath and urine samples for 12 weeks
- English speaking
- willing to sign informed consent
Exclusion criteria:
- serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk)
- dementia (<23 on the Mini Mental State Exam; Folstein et al. 1975)
- in recovery from pathological gambling
Contacts and Locations| United States, Connecticut | |
| University of Connecticut Health Center | |
| Farmington, Connecticut, United States, 06030 | |
| Principal Investigator: | Nancy Petry, Ph.D. | University of Connecticut Health Center |
More Information
No publications provided
| Responsible Party: | University of Connecticut Health Center |
| ClinicalTrials.gov Identifier: | NCT00249717 History of Changes |
| Other Study ID Numbers: | NIDA-18883-1, R01DA018883 |
| Study First Received: | November 3, 2005 |
| Last Updated: | November 17, 2011 |
| Health Authority: | United States: Federal Government United States: Institutional Review Board |
Keywords provided by University of Connecticut Health Center:
|
Contingency management Substance abuse treatment |
Additional relevant MeSH terms:
|
Substance-Related Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 21, 2013